Why Analysts Believe RAC is “Highly Undervalued”, page-114

That is certainly one area that Triangle were very conservative with - everyone has been predicting a decline in anthracycline use for more than a decade, yet every year the usage goes up as the population grows and ages.

The big area where Triangle was very conservative is they just applied a 50% hair cut across all their numbers. So far I have not seen any analysis from anyone that Triangle are overestimating the market size. We should also not forget this is all just for the cardioprotection indication alone.

I know from personal experience that it would make life for Race easier if the numbers weren’t so huge - when you talk to someone new to Race about the scale of opportunity you come off as a BS artist because it just seems unreal. It is much easier to sell an opportunity that will treat only ever 100 patients worldwide, than it is to sell an opportunity on the scale of Bisantrene.